Has Henry Kwong, MD received payments from drug or device companies?

Yes. Drug and device makers reported $147,475 in general payments to Henry Kwong, MD across 354 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Kwong, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Kwong, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Kwong, MD

Retina Specialist · Phoenix, AZNPI 1033257746

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (55.5%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 80.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $57,162 and has fallen 91.9% since, to $4,644 in 2025. Among retina specialist clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$147,475in general payments, 2019–2025

Across 354 payments — averaging $416.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

US Retina LLC$119K
Dutch Ophthalmic, USA$8K
Regeneron$3K
Regeneron Healthcare Solutions, Inc.$3K
Bausch & Lomb Americas Inc.$3K
Alimera Sciences, Inc.$2K
plus $9K from 24 others

$3,269,671in research payments, 2019–2025

Across 518 payments — averaging $6312.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$1.7M
Ocular Therapeutix, Inc.$452K
Boehringer Ingelheim$409K
AstraZeneca$402K
Roche TCRC, Inc.$207K
Boehringer Ingelheim International GmbH$65K
plus $38K from 4 others

What the payments were for

Consulting fees$7,8075%
Travel & lodging$5,3264%
Food & beverage$15,41510%
Education$150%
Gifts$190%
Ownership interest$37,10225%
Other$81,79155%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
US Retina LLC	13	$119,057
Dutch Ophthalmic, USA	18	$8,474
Regeneron	12	$3,376
Regeneron Healthcare Solutions, Inc.	89	$3,068
Bausch & Lomb Americas Inc.	24	$2,716
Alimera Sciences, Inc.	26	$2,162
Ocular Therapeutix, Inc.	5	$1,902
Genentech USA, Inc.	32	$1,001
F. Hoffmann-la Roche AG	1	$785
AbbVie(2 entities)	42	$767
Eyepoint US, Inc.	18	$737
Alcon	12	$593
Astellas Pharma US Inc	13	$434
Iridex Corporation	4	$361
Apellis Pharmaceuticals, Inc.	10	$317
Carl Zeiss Meditec USA, Inc.	3	$232
Novartis	7	$225
Glaukos Corporation	2	$205
Genentech, Inc.	2	$201
Alcon Research LLC	1	$182
Bausch & Lomb, A Division Of Bausch Health US, LLC	2	$165
Mallinckrodt Hospital Products Inc.	2	$136
Harrow Eye, LLC	3	$93
Coherus Oncology, Inc.	3	$72
Mallinckrodt Enterprises LLC	2	$48
Biogen	2	$46
ANI Pharmaceuticals, Inc.	2	$39
Rhythm Pharmaceuticals, Inc.	2	$33
Spark Therapeutics, Inc.	1	$28
Carl Zeiss Meditec AG	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,475 in reported general payments places this provider in the 90th percentile of 30 retina specialist providers in Arizona.

See all retina specialist providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,158,536

Medicare patients

1,340

Services billed

15,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	159	$6,864
Brimonidine Tartrate	20	$2,232
Ofloxacin	126	$1,308
Ketorolac Tromethamine	59	$1,305
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	14	$192
Timolol Maleate	14	$150

Paid to pharmacies, not to this prescriber.

Other retina specialist in Phoenix

Jordan GraffPhoenix$483K
Rahul ReddyPhoenix$333K
Benjamin BakallPhoenix$137K
Jaime GaitanPhoenix$114K
Stephen de SouzaPhoenix$95K
Joseph BryanPhoenix$88K
Alan GordonPhoenix$86K
Suhail AlamPhoenix$24K
Rima PatelPhoenix$19K
Matthew WelchPhoenix$16K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →